ABBVIE INC. vs. Lexicon Pharmaceuticals, Inc.
ABBVIE INC. (ABBV) comes out ahead, leading on 7 of 8 compared factors.
Size & Scale
| ABBV | LXRX | |
|---|---|---|
| Market Cap | $438.19 billion | $1.07 billion |
| Revenue (TTM) | $64.39 billion | $41.47 million |
| Net Income (TTM) | $6.32 billion | $-61,117,000 |
ABBV leads on 3 of 3 size & scale factors.
Valuation
| ABBV | LXRX | |
|---|---|---|
| P/E Ratio | 70.05 | — |
| Price / Book | -74.42 | 6.12 |
| Price / Sales | 6.81 | 25.75 |
ABBV leads on 2 of 2 valuation factors.
Profitability
| ABBV | LXRX | |
|---|---|---|
| Net Margin | 9.81% | -147.38% |
| Return on Equity | -107.29% | -35.02% |
ABBV and LXRX split the profitability factors evenly.
Dividend
| ABBV | LXRX | |
|---|---|---|
| Dividend Yield | 2.79% | — |
| Payout Ratio | 195.48 | — |
ABBV and LXRX split the dividend factors evenly.
Risk & Sentiment
| ABBV | LXRX | |
|---|---|---|
| Short Interest | 0.85% | 2.42% |
ABBV leads on 1 of 1 risk & sentiment factors.
Dig deeper: ABBV overview, ABBV financials, LXRX overview, LXRX financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.